NASHVILLE, Tenn. / Oct 26, 2023 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA) today announced the Company will host its 2023 Investor Day with analysts and institutional investors on Thursday, November 9, 2023, beginning at 8:00 a.m. CT.
A team of HCA Healthcare leaders will offer perspectives on the Company’s financial performance, operations, and strategies to drive growth and create value. In conjunction with Investor Day, the Company plans to provide early perspectives on the outlook for 2024 and longer-term financial targets.
The Company will stream the presentations and the management question and answer portion of Investor Day and will make conference materials available on its Investor Relations page (https://investor.hcahealthcare.com/events-and-presentations/default.aspx) at approximately 6:30 a.m. CT on November 9, 2023. Investor Day is expected to conclude at approximately 3:45 p.m. CT. A replay will be available on the Company website beginning Friday, November 10, 2023, at 4:00 p.m. CT.
About the Company
As of September 30, 2023, HCA Healthcare operated 183 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.
| Last Trade: | US$381.39 |
| Daily Change: | 2.74 0.72 |
| Daily Volume: | 2,095,552 |
| Market Cap: | US$96.610B |
April 25, 2025 February 20, 2025 February 18, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
